2025
Chronic chemotherapy-induced peripheral neuropathy: living with neuropathy during and after cancer treatments
Rahman N, Sukumar J, Lustberg M. Chronic chemotherapy-induced peripheral neuropathy: living with neuropathy during and after cancer treatments. Annals Of Palliative Medicine 2025, 14: 19616-19216. PMID: 40211744, DOI: 10.21037/apm-24-154.Peer-Reviewed Original ResearchConceptsQuality of lifeChemotherapy-induced peripheral neuropathyFunctional statusPrevalence of chemotherapy-induced peripheral neuropathyImpact of chemotherapy-induced peripheral neuropathyTreatment strategiesAssociated with riskPatients experience symptomsCancer survivorsCurrent treatment strategiesPatient experiencePeripheral nerve damageDebilitating side effectsPrevention strategiesSymptoms of sadnessDose adjustmentPsychological impactClinical presentationClinical factorsNerve damagePeripheral neuropathyChemotherapeutic agentsSymptomatic reliefRisk factorsDiagnostic evaluation
2024
Depression and anxiety management in cirrhosis
Zimbrean P, Jakab S. Depression and anxiety management in cirrhosis. Hepatology Communications 2024, 9: e0600. PMID: 39670879, PMCID: PMC11637748, DOI: 10.1097/hc9.0000000000000600.Peer-Reviewed Original ResearchConceptsAnxiety disordersAnxiety symptomsPrevalence of generalized anxiety disorderDiagnosis of depressionPrevalence of depressionGeneral populationAnxietyScreening instrumentAnxiety managementTreatment interventionsDepressionPsychotherapyDisordersHealth-related quality of lifeLiver diseaseIntegrated care approachSymptomsHealth-related qualitySevere symptomsPharmacological agentsStand-alone therapyQuality of lifeCare approachAntidepressantsDose adjustmentBuprenorphine: An anesthesia-centric review.
Hickey T, Acampora G. Buprenorphine: An anesthesia-centric review. Journal Of Opioid Management 2024, 20: 503-527. PMID: 39775451, DOI: 10.5055/jom.0901.Peer-Reviewed Original ResearchConceptsOpioid use disorderEffective analgesic alternativeEffective opioid analgesicOpioid-tolerant patientsMultimodal analgesia strategyLong duration of actionPatients prescribed buprenorphineChronic pain managementDiscontinuation of buprenorphineFormulation of buprenorphineDuration of actionAnalgesic alternativeContinuing buprenorphineDose adjustmentNonopioid analgesicsAnalgesia strategyOpioid analgesicsChronic painImprove patient outcomesTemporary discontinuationPerioperative painPain managementPerioperative periodBuprenorphineUse disorderHematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Chojecki A, Boselli D, Dortilus A, Hamadeh I, Begley S, Chen T, Bose R, Podoltsev N, Zeidan A, Balmaceda N, Yacoub A, Ai J, Knight T, Ragon B, Shah N, Sanikommu S, Symanowski J, Mesa R, Grunwald M. Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice. Annals Of Hematology 2024, 103: 2837-2843. PMID: 38662203, PMCID: PMC11283405, DOI: 10.1007/s00277-024-05735-7.Peer-Reviewed Original ResearchFollow-up durationPolycythemia veraThrombotic riskClinical practiceMedian follow-up durationHematocrit controlHematocrit levelsCohort study of patientsLow thrombotic riskUS Food and Drug AdministrationMonths of treatmentRisk of thrombosisStudy of patientsJanus kinase inhibitorsResponse to hydroxyureaFood and Drug AdministrationRed blood cell productionBlood cell productionCytoreductive treatmentPainful splenomegalyDose adjustmentMyeloproliferative neoplasmsPlatelet countThrombotic eventsArterial thromboses
2023
Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Zeidan A, Savona M, Madanat Y, Fenaux P, Komrokji R, Jonášová A, Illmer T, Sun L, Berry T, Feller F, Navada S, Santini V, Platzbecker U. Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS). Blood 2023, 142: 6478. DOI: 10.1182/blood-2023-180962.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsLower-risk myelodysplastic syndromesPhase 3 trialManagement of cytopeniasGrade 3Placebo groupDose adjustmentMedian timeTreatment delayDose reductionInternational Prognostic Scoring System risk groupsHematologic treatment-emergent adverse eventsRed blood cell transfusion dependencyImetelstat treatmentExperienced grade 3RBC transfusion burdenRBC transfusion independenceTreatment cycles 1Grade 4 neutropeniaGrade 4 thrombocytopeniaPrimary end pointGrowth factor supportErythropoiesis-stimulating agentsCycle 1High telomerase activityOpen‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
Mayo M, Vierling J, Bowlus C, Levy C, Hirschfield G, Neff G, Galambos M, Gordon S, Borg B, Harrison S, Thuluvath P, Goel A, Shiffman M, Swain M, Jones D, Trivedi P, Kremer A, Aspinall R, Sheridan D, Dörffel Y, Yang K, Choi Y, McWherter C. Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Alimentary Pharmacology & Therapeutics 2023, 59: 186-200. PMID: 37904314, DOI: 10.1111/apt.17755.Peer-Reviewed Original ResearchConceptsPrimary biliary cholangitisBiliary cholangitisLiver injurySerious treatment-related adverse eventsBiochemical markersLong-term extension studyTreatment-related adverse eventsAnti-pruritic effectsClinical trial extensionsSecondary efficacy analysesTwo-Year SafetyUnexpected histological findingsNon-alcoholic steatohepatitisLong-term safetyAdverse eventsElevated bilirubinComposite endpointDose adjustmentEfficacy analysisHistological findingsTrial extensionEfficacy dataEfficacy resultsSelective peroxisomePatientsRandomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study
Sanft T, Harrigan M, McGowan C, Cartmel B, Zupa M, Li F, Ferrucci L, Puklin L, Cao A, Nguyen T, Neuhouser M, Hershman D, Basen-Engquist K, Jones B, Knobf T, Chagpar A, Silber A, Tanasijevic A, Ligibel J, Irwin M. Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study. Journal Of Clinical Oncology 2023, 41: 5285-5295. PMID: 37656930, PMCID: PMC10691793, DOI: 10.1200/jco.23.00871.Peer-Reviewed Original ResearchConceptsRelative dose intensityPathologic complete responseProportion of patientsBreast cancerNeoadjuvant chemotherapyChemotherapy completionComplete responseNutrition interventionsHigher pathologic complete responseHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Triple-negative breast cancerChemotherapy dose adjustmentsHome-based exerciseGrowth factor receptor 2Breast cancer outcomesEffects of exerciseFactor receptor 2Electronic medical recordsChi-square testUsual careDose intensityExercise interventionDose adjustmentRandomized trialsHIV and Associated TB: A Lethal Association for Kidney Health?
Kalyesubula R, Wearne N, Kubo M, Hussey N, Naicker S. HIV and Associated TB: A Lethal Association for Kidney Health? Seminars In Nephrology 2023, 43: 151470. PMID: 38245391, DOI: 10.1016/j.semnephrol.2023.151470.Peer-Reviewed Original ResearchHuman immunodeficiency virusKidney diseaseHIV/TB coinfectionAvoidance of drug-drug interactionsLower-middle-income countriesDrug dose adjustmentDecline of kidney functionKidney function monitoringDrug-drug interactionsMechanisms of kidney diseasesHIV/TB patientsLow-incomeDose adjustmentImmunodeficiency virusClinical presentationDiagnose CKDKidney transplantationKidney functionInfectious causesIncreased riskKidney healthGenetic susceptibilityFunction monitoringPatientsKidneyAssociation of adherence to individual components of Society of Thoracic Surgeons cardiac surgery antibiotic guidelines and postoperative infections
Bardia A, Michel G, Farela A, Fisher C, Mori M, Huttler J, Lang A, Geirsson A, Schonberger R. Association of adherence to individual components of Society of Thoracic Surgeons cardiac surgery antibiotic guidelines and postoperative infections. Journal Of Thoracic And Cardiovascular Surgery 2023, 167: 2170-2176.e5. PMID: 37075942, PMCID: PMC10579454, DOI: 10.1016/j.jtcvs.2023.03.031.Peer-Reviewed Original ResearchWeight-adjusted dosingPostoperative infectionAntibiotic guidelinesIncidence of nonadherenceCoronary artery bypassTertiary care hospitalAssociation of adherenceCohort of patientsRetrospective observational studyPost-operative infectionIntraoperative redosingValvular surgeryAntibiotic timingArtery bypassCoronary revascularizationPostoperative complicationsPostoperative sepsisAdult patientsFirst doseAntibiotic choiceCardiac surgeryCardiopulmonary bypassCare hospitalDose adjustmentPrimary outcomeIncidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis
Liverman R, Serluco A, Nance G, George R, Rodriguez D, Deshpande S, Mao C, Garro R, Yildirim I. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis. Pediatric Transplantation 2023, 27: e14493. PMID: 36945819, DOI: 10.1111/petr.14493.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsPediatric solid organ transplant recipientsCytomegalovirus DNAemiaValganciclovir prophylaxisDose reductionRisk factorsTransplant recipientsImpact of dose adjustmentsRisk factors associated with failureFactors associated with failureOrgan transplant recipientsHeart transplant recipientsIndependent risk factorRetrospective cohort studyAssociated with morbidityCMV DNAemiaCytomegalovirus eventsValganciclovir dosingImmunosuppressive therapyDose adjustmentYounger age groupsDNAemiaValganciclovirRisk stratificationAdverse eventsBaseline platelet serotonin in a multi-site treatment study of depression in veterans administration patients: Distribution and effects of demographic variables and serotonin reuptake inhibitors
Anderson G, Ramsey C, Lynch K, Gelernter J, Oslin D. Baseline platelet serotonin in a multi-site treatment study of depression in veterans administration patients: Distribution and effects of demographic variables and serotonin reuptake inhibitors. Journal Of Affective Disorders 2023, 327: 368-377. PMID: 36754092, DOI: 10.1016/j.jad.2023.02.017.Peer-Reviewed Original ResearchConceptsReuptake inhibitorsVeterans Administration patientsTreatment studiesSubset of patientsNorepinephrine reuptake inhibitorsCross-sectional studyEffect of ageDose adjustmentAfrican American individualsDemographic variablesMean plateletDrug exposurePlatelet serotoninSerotonin valuesPatientsClinical implicationsHealth recordsMale groupSSRIsDepressionPlateletsEuropean AmericansInhibitorsSex differencesGroup means
2022
Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
Dosne A, Li X, Luo M, Nnane I, Dimopoulos M, Terpos E, Sonneveld P, Kampfenkel T, Carson R, Amin H, Ruixo J, Zhou H, Sun Y, Xu Y. Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma. British Journal Of Clinical Pharmacology 2022, 89: 1640-1655. PMID: 36484341, DOI: 10.1111/bcp.15628.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsExposure-response analysesPPK analysisPPK modelTwo-compartment PPK modelExposure to daratumumabProgression-free survivalNo dose adjustmentRefractory multiple myelomaExposure-responseTreatment of patientsClinically relevant effectsConcentration-time dataDaratumumab administrationDaratumumab exposureDaratumumab monotherapyDose adjustmentDosing regimenCharacterize pharmacokineticsMultiple myelomaPK samplingDaratumumabAdverse eventsPopulation pharmacokineticsPK exposureEfficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants
Bikdeli B, Tajrishi F, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, Siegal DM, Eikelboom JW, Monreal M, Jimenez D, Connors JM, Ageno W, Barnes GD, Piazza G, Angiolillo DJ, Parikh SA, Kirtane AJ, Lopes RD, Bhatt DL, Weitz JI, Mehran R, Krumholz HM, Goldhaber SZ, Lip GYH. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology 2022, 7: 747-759. PMID: 35648414, DOI: 10.1001/jamacardio.2022.1292.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsRandomized clinical trialsAcute VTE treatmentDose adjustmentOral anticoagulantsLow-intensity treatmentPrimary preventionLarge registriesVTE treatmentHigh-risk medical patientsStable atherosclerotic vascular diseaseHigh-risk cancer patientsLarge randomized clinical trialsSecondary VTE preventionPeripheral artery diseaseAtherosclerotic vascular diseaseDaily clinical practiceRoutine practice patternEvidence of safetyRecent revascularizationStroke preventionVTE preventionArtery diseaseMedical patientsCancer patients
2021
Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis
Luo M, Zhu P, Nnane I, Xiong Y, Merlini G, Comenzo R, Kastritis E, Wechalekar A, Weiss B, Tran N, Qin X, Vermeulen J, Sharma A, Sun Y, Zhou H. Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis. The Journal Of Clinical Pharmacology 2021, 62: 656-669. PMID: 34708423, DOI: 10.1002/jcph.1994.Peer-Reviewed Original ResearchConceptsLight chain amyloidosisSafety end pointSystemic exposureExposure-response analysesEnd pointsPopulation pharmacokineticsAmyloid light-chain amyloidosisNo dose adjustmentEfficacy end pointSystemic amyloid light-chain amyloidosisExposure-responseTreatment of light-chain amyloidosisImpact of potential covariatesLogistic regression analysisNonlinear mixed-effects modelingConcentration-time dataDexamethasone regimenDose adjustmentHematologic responseDaratumumabImmunogenicity dataPopPK analysisPopPK modelImpact of Low-Dose Fluconazole on Tacrolimus Dosing in Renal Transplant
Johnston JP, Cohen EA, Casal GH, Asch WS, Reardon DP. Impact of Low-Dose Fluconazole on Tacrolimus Dosing in Renal Transplant. Journal Of Pharmacy Practice 2021, 35: 701-706. PMID: 33759619, DOI: 10.1177/08971900211000702.Peer-Reviewed Original ResearchConceptsLow-dose fluconazoleRenal transplant patientsAdverse drug reactionsTAC levelsTransplant patientsGraft rejectionDrug reactionsTherapeutic levelsSingle-center retrospective chart reviewPost-operative day 10Azole antifungal therapySubtherapeutic tacrolimus levelsTAC dose adjustmentRenal transplant recipientsTotal daily doseRetrospective chart reviewTacrolimus dosingTacrolimus levelsRenal transplantTransplant recipientsChart reviewSecondary outcomesDaily doseDose adjustmentPrimary outcome
2020
Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors
Trendowski MR, Wheeler HE, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Einhorn LH, Travis LB, Dolan ME. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clinical Cancer Research 2020, 26: 6550-6558. PMID: 32998964, PMCID: PMC7744329, DOI: 10.1158/1078-0432.ccr-20-2682.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBleomycinCancer SurvivorsCisplatinEtoposideFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGenome-Wide Association StudyHumansIfosfamideMaleMiddle AgedNeoplasmsNeurotoxicity SyndromesPolymorphism, Single NucleotidePrognosisRisk FactorsSurvival RateVinblastineConceptsCumulative cisplatin doseCisplatin doseSevere neurotoxicityCancer survivorsRisk factorsAdult-onset cancer survivorsLifestyle/behavioral factorsCisplatin-induced neurotoxicityDizziness/vertigoNeuro-otological symptomsPeripheral sensory neuropathyPoor overall healthPeripheral motor neuropathyImportant risk factorTesticular cancer survivorsQuality of lifeSerum platinum levelsDose adjustmentMotor neuropathyRaynaud's phenomenonSensory neuropathyNeurotoxicity riskPsychotropic medicationsClinical examinationMedical historyInsulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes
Nimri R, Battelino T, Laffel LM, Slover RH, Schatz D, Weinzimer SA, Dovc K, Danne T, Phillip M. Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nature Medicine 2020, 26: 1380-1384. PMID: 32908282, DOI: 10.1038/s41591-020-1045-7.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin dose adjustmentPhysician armDose adjustmentAcademic diabetes centerInsulin pump settingsPrimary efficacy measureSevere adverse eventsTarget glucose rangeInsulin pump therapyNon-inferiority trialArtificial intelligence-based decision support systemAdverse eventsInsulin titrationDiabetes CenterEfficacy measuresPump therapyPercentage of timePercentage of readingsGlucose levelsSix monthsContinuous glucose monitoring devicesDiabetesInsulin pumpGlucose monitoring devicesHow to determine kidney function in cancer patients?
Sprangers B, Abudayyeh A, Latcha S, Perazella MA, Jhaveri KD. How to determine kidney function in cancer patients? European Journal Of Cancer 2020, 132: 141-149. PMID: 32361629, DOI: 10.1016/j.ejca.2020.03.026.Peer-Reviewed Original ResearchConceptsGlomerular filtration rateKidney functionCancer patientsDifferent glomerular filtration ratesAppropriate dose adjustmentCKD-EPI formulaSerum creatinine concentrationNarrow therapeutic indexDose adjustmentFiltration rateClinical trialsCreatinine concentrationTherapeutic indexAnti-cancer drugsPatientsToxic drugsDrugsBody surfaceTrialsAn Analysis of Anesthesia Induction Dosing in Female Older Adults
Chen EY, Michel G, Zhou B, Dai F, Akhtar S, Schonberger RB. An Analysis of Anesthesia Induction Dosing in Female Older Adults. Drugs & Aging 2020, 37: 435-446. PMID: 32300966, PMCID: PMC7359723, DOI: 10.1007/s40266-020-00760-3.Peer-Reviewed Original ResearchConceptsAcute kidney injuryPostinduction hypotensionGeneral anesthesiaPresent cohortPostoperative acute kidney injuryLarge tertiary teaching hospitalOlder adultsFrailty of patientsGynecologic oncology surgeryImmediate hemodynamic effectsPropofol induction dosesPercentage of patientsRetrospective observational studyTertiary teaching hospitalPerioperative vital signsHigher propofol dosesFemale older adultsAKI associationInotrope administrationKidney injurySurgical populationHemodynamic effectsDose adjustmentPrimary outcomeFemale patients
2019
Pharmacist recommendations for prophylactic enoxaparin monitoring and dose adjustment in trauma patients admitted to a surgical intensive care unit
Scrimenti A, Seabury RW, Miller CD, Ruangvoravat L, Darko W, Probst LA, Cwikla GM. Pharmacist recommendations for prophylactic enoxaparin monitoring and dose adjustment in trauma patients admitted to a surgical intensive care unit. Pharmacy Practice 2019, 17: 1541-1541. PMID: 31897248, PMCID: PMC6935549, DOI: 10.18549/pharmpract.2019.4.1541.Peer-Reviewed Original ResearchSurgical intensive care unitPharmacist recommendationsTrauma patientsAnti-factor XaIntensive care unitDose adjustmentMedical providersEnoxaparin doseProphylactic enoxaparinTrough concentrationsCare unitEnoxaparin dosesVTE prophylaxisChart reviewAdult patientsPharmacist participationPatientsEnoxaparinFinal analysisPharmacistsSteady-state concentrationsDoseIRB reviewProvidersLimited information
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply